Re-evaluating Optimal Vaccine Schedules against Ebola (REVOLVE)

Thank you for taking part in previous studies to evaluate vaccines against Ebola virus disease. We are now inviting participants to take part in a new study.

What is the purpose of the study?

In this study we want to learn more about the persistence of the immune response 2-5 years following the initial dose of an Ebola virus vaccine and whether a “late” booster dose of the Ad26.ZEBOV Ebola vaccine would increase the duration of the response.

Investigating a new Vaccine Against Meningitis B in Oxford VAMBOX

You are invited to take part in a study to investigate a new Vaccine Against Meningitis B in Oxford (VAMBOX). The study is being run by the Oxford Vaccine Group at the University of Oxford.

If you are 18 to 50 yrs old and are in good health, then you may be eligible to take part in the study. We will provide reimbursement for your time, inconvenience and travel. Participants will receive up to £630.00 if they remain in the study for the entire period. The total study participation time is 12 months.


Persistence of the immune response after immunisation with Ebola virus vaccines (PRISM Study)

The Oxford Vaccine Group is inviting participants of the ‘Evaluating Optimal Vaccine Schedules against Ebola’ (EVOLVE) vaccine study to take part in a study looking at the persistence of immunity induced by the vaccines administered in that study (Ad26.ZEBOV and MVA-BN-Filo).